Company intelligence / Profile preview

Neuropix

Ownership: Private
Development stage: Other

Overview

Neuropix has developed a CE-marked, non-invasive wearable neurostimulation device that delivers auricular vagus nerve stimulation. Clinical use is reported in major hospitals across Hong Kong and Taiwan with improvements seen within two weeks for anxiety, stress, sleep quality, depression, migraine, and epilepsy. Expansion into aging-related diseases is underway.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-invasive neurostimulation device
Industry: Therapeutic Medical Devices

Partnerships

Not specifically named but open to healthcare and industry partnerships; active collaborations with major hospitals in Hong Kong & Taiwan.

Beyond the preview

Go deeper on Neuropix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuropix.

Explore the full profile